The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

In the US, if a patented drug is in short supply, compounding pharmacies can legally produce and sell it. Entrepreneurs capitalized on this during GLP-1 shortages by buying raw API from China, creating their own versions, and generating billions in high-margin revenue—a risk large pharma companies avoid due to litigation fears.

Formula One heavily restricts and penalizes teams for using traditional wind tunnels to control costs. This regulatory pressure created the perfect market opening for Skin Systems' cheaper, more effective "smart tape" solution, which circumvents these expensive, time-limited resources.

Companies in regulated industries like pharma and nicotine can achieve rapid revenue growth by exploiting marketing's gray areas. However, this strategy attracts regulatory penalties and lawsuits, often reducing the company's long-term enterprise value to near zero due to the associated risks.

Investors often misinterpret the impact of complex regulatory changes, causing price moves based on noise rather than substance. This creates arbitrage opportunities for firms that can accurately differentiate between consequential rules and those that ultimately don't matter.

The strategy is to acquire biotech companies at valuations justified by a narrow clinical indication (e.g., premature ejaculation). The massive return comes from the "free option" of the much larger off-label consumer market (e.g., all men wanting to last longer) that is not priced in.

Previously considered a capital-efficient area due to regulatory flexibility, the rare disease and gene therapy space is now perceived as high-risk. The FDA is applying greater scrutiny and tightening standards, making development more unpredictable for sponsors.

The anticipated approval of psychedelic drugs faces a major manufacturing hurdle: a shortage of CDMOs registered to handle Schedule I substances. The few available facilities are often dominated by large pharma companies producing other controlled drugs, which will create a capacity crunch for smaller psychedelic biotechs.